Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,147
archived clinical trials in
Asthma

Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Winston-Salem, NC
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Philadelphia, PA
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Greenville, SC
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Lufkin, TX
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Lufkin, TX
Click here to add this to my saved trials
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Richmond, VA
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Madison, WI
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Madison, WI
Click here to add this to my saved trials
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Berazategui,
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Berazategui,
Click here to add this to my saved trials
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Brooklyn, NY
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Oklahoma City, OK
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma
Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma
Status: Enrolling
Updated:  12/31/1969
University of Virginia Fontaine Research Park
mi
from
Charlottesville, VA
Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma
Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma
Status: Enrolling
Updated: 12/31/1969
University of Virginia Fontaine Research Park
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Birmingham, AL
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Roseville, CA
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Roseville, CA
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Charlotte, NC
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Piscataway, NJ
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Piscataway, NJ
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Williamsburg, VA
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Williamsburg, VA
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Riverside, CA
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Riverside, CA
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Richmond, VA
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Upland, CA
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Upland, CA
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
East Providence, RI
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
East Providence, RI
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
San Diego, CA
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Baltimore, MD
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Rochester, NY
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Durham, NC
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Florencio Varela,
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Florencio Varela,
Click here to add this to my saved trials
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Madison, WI
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials
Cockroach Nasal Allergen Challenge Pilot
A Pilot Study to Assess Safety and Feasibility of Cockroach Nasal Allergen Challenge in Cockroach Sensitive Children and Adults With Asthma (ICAC-27)
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital
mi
from
Cincinnati, OH
Cockroach Nasal Allergen Challenge Pilot
A Pilot Study to Assess Safety and Feasibility of Cockroach Nasal Allergen Challenge in Cockroach Sensitive Children and Adults With Asthma (ICAC-27)
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cockroach Nasal Allergen Challenge Pilot
A Pilot Study to Assess Safety and Feasibility of Cockroach Nasal Allergen Challenge in Cockroach Sensitive Children and Adults With Asthma (ICAC-27)
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Cockroach Nasal Allergen Challenge Pilot
A Pilot Study to Assess Safety and Feasibility of Cockroach Nasal Allergen Challenge in Cockroach Sensitive Children and Adults With Asthma (ICAC-27)
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Cockroach Nasal Allergen Challenge Pilot
A Pilot Study to Assess Safety and Feasibility of Cockroach Nasal Allergen Challenge in Cockroach Sensitive Children and Adults With Asthma (ICAC-27)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Colorado
mi
from
Aurora, CO
Cockroach Nasal Allergen Challenge Pilot
A Pilot Study to Assess Safety and Feasibility of Cockroach Nasal Allergen Challenge in Cockroach Sensitive Children and Adults With Asthma (ICAC-27)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Cockroach Nasal Allergen Challenge Pilot
A Pilot Study to Assess Safety and Feasibility of Cockroach Nasal Allergen Challenge in Cockroach Sensitive Children and Adults With Asthma (ICAC-27)
Status: Enrolling
Updated:  12/31/1969
Childrens National Medical Center
mi
from
Washington,
Cockroach Nasal Allergen Challenge Pilot
A Pilot Study to Assess Safety and Feasibility of Cockroach Nasal Allergen Challenge in Cockroach Sensitive Children and Adults With Asthma (ICAC-27)
Status: Enrolling
Updated: 12/31/1969
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Effect of Fasting and Refeeding on T-cell Fate
Pilot Study to Evaluate the Effect of Fasting and Refeeding on T-Cell Fate
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Effect of Fasting and Refeeding on T-cell Fate
Pilot Study to Evaluate the Effect of Fasting and Refeeding on T-Cell Fate
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation
A Randomized Double Blinded Placebo Controlled Trial of One Versus Two Doses of Oral Dexamethasone for the Treatment of Acute Asthma Exacerbation in the Pediatric Emergency Department (ED)
Status: Enrolling
Updated:  12/31/1969
New York Methodist Hospital
mi
from
Brooklyn, NY
Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation
A Randomized Double Blinded Placebo Controlled Trial of One Versus Two Doses of Oral Dexamethasone for the Treatment of Acute Asthma Exacerbation in the Pediatric Emergency Department (ED)
Status: Enrolling
Updated: 12/31/1969
New York Methodist Hospital
mi
from
Brooklyn, NY
Click here to add this to my saved trials
T Regulatory and Childhood Asthma
T Regulatory and Childhood Asthma
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin
mi
from
Madison, WI
T Regulatory and Childhood Asthma
T Regulatory and Childhood Asthma
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Childhood Origins of Asthma (COAST)
Rhinovirus Infection and Asthma in Childhood and Adolescents
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin
mi
from
Madison, WI
Childhood Origins of Asthma (COAST)
Rhinovirus Infection and Asthma in Childhood and Adolescents
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
National Survey of Lead and Allergen Hazards in Housing
National Survey of Lead Hazards and Allergens in Housing
Status: Enrolling
Updated:  12/31/1969
NIEHS, Research Triangle Park
mi
from
Research Triangle Park, NC
National Survey of Lead and Allergen Hazards in Housing
National Survey of Lead Hazards and Allergens in Housing
Status: Enrolling
Updated: 12/31/1969
NIEHS, Research Triangle Park
mi
from
Research Triangle Park, NC
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1029 or Placebo in Patients With Mild to Moderate Asthma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Costa Mesa, CA
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1029 or Placebo in Patients With Mild to Moderate Asthma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1029 or Placebo in Patients With Mild to Moderate Asthma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rolling Hills Estates, CA
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1029 or Placebo in Patients With Mild to Moderate Asthma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rolling Hills Estates, CA
Click here to add this to my saved trials
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1029 or Placebo in Patients With Mild to Moderate Asthma
Status: Enrolling
Updated:  12/31/1969
Merck Sharp & Dohme
mi
from
North Ryde,
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-1029 or Placebo in Patients With Mild to Moderate Asthma
Status: Enrolling
Updated: 12/31/1969
Merck Sharp & Dohme
mi
from
North Ryde,
Click here to add this to my saved trials
LungVITamin D and OmegA-3 Trial (lungVITAL)
LungVITamin D and OmegA-3 Trial
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
LungVITamin D and OmegA-3 Trial (lungVITAL)
LungVITamin D and OmegA-3 Trial
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Assessing Risk of Food Insecurity Within Households of Children With Food Allergy
Assessing Risk of Food Insecurity Within Households of Children With Food Allergy
Status: Enrolling
Updated:  12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
Assessing Risk of Food Insecurity Within Households of Children With Food Allergy
Assessing Risk of Food Insecurity Within Households of Children With Food Allergy
Status: Enrolling
Updated: 12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rolling Hills Estates, CA
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rolling Hills Estates, CA
Click here to add this to my saved trials
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Colorado Springs, CO
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Louisville, KY
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Owensboro, KY
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Owensboro, KY
Click here to add this to my saved trials
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chevy Chase, MD
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Minneapolis, MN
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Missoula, MT
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Missoula, MT
Click here to add this to my saved trials
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Papillion, NE
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Papillion, NE
Click here to add this to my saved trials
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials